BR0109220A - Composições compreendendo bloqueadores de transferência de célula renal de l-dopa para o tratamento do mal de parkinson - Google Patents

Composições compreendendo bloqueadores de transferência de célula renal de l-dopa para o tratamento do mal de parkinson

Info

Publication number
BR0109220A
BR0109220A BR0109220-0A BR0109220A BR0109220A BR 0109220 A BR0109220 A BR 0109220A BR 0109220 A BR0109220 A BR 0109220A BR 0109220 A BR0109220 A BR 0109220A
Authority
BR
Brazil
Prior art keywords
dopa
renal cell
parkinson
cell transfer
phenyl
Prior art date
Application number
BR0109220-0A
Other languages
English (en)
Inventor
Patricio Soares-Da-Silva
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Publication of BR0109220A publication Critical patent/BR0109220A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES COMPREENDENDO BLOQUEADORES DE TRANSFERêNCIA DE CéLULA RENAL DE L-DOPA PARA O TRATAMENTO DO MAL DE PARKINSON". Uma composição farmacêutica para o tratamento do mal de Parkinson compreende L-DOPA e pelo menos um composto capaz de bloquear o percurso de transferência externa de célula renal de L-DOPA; dito composto bloqueador sendo escolhido dentre (a) um derivado de benzopiran de fenila flavonóide; (b) um derivado de trans-estilbeno; ou (c) floretin [3-(4-hidróxi-fenil)-1-(2,4,6-tri-hidróxi-fenil)-1-propanona]. A composição pode também compreender um inibidor da enzima amino ácido decarboxilase (AADC), uma tal carbidopa ou benserazida, e/ou um inibidor da enzima catecol-o-metil transferase (COMT), tal como entacapona ou tolcapona. A composição é preferencialmente administrada na forma sólida e a L-DOPA pode ser administrada simultaneamente ou seq³encialmente com o composto bloqueador de transferência externa de célula renal de L-DOPA.
BR0109220-0A 2000-03-14 2001-03-13 Composições compreendendo bloqueadores de transferência de célula renal de l-dopa para o tratamento do mal de parkinson BR0109220A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0006063A GB2348371B (en) 2000-03-14 2000-03-14 Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
PCT/EP2001/002896 WO2001068065A2 (en) 2000-03-14 2001-03-13 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
BR0109220A true BR0109220A (pt) 2003-03-18

Family

ID=9887552

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109220-0A BR0109220A (pt) 2000-03-14 2001-03-13 Composições compreendendo bloqueadores de transferência de célula renal de l-dopa para o tratamento do mal de parkinson

Country Status (23)

Country Link
US (1) US20040242503A1 (pt)
EP (1) EP1267853B1 (pt)
JP (1) JP3677002B2 (pt)
KR (1) KR100738746B1 (pt)
CN (1) CN1262269C (pt)
AR (1) AR035567A1 (pt)
AT (1) ATE275397T1 (pt)
AU (1) AU781280B2 (pt)
BR (1) BR0109220A (pt)
CA (1) CA2402712C (pt)
CZ (1) CZ297123B6 (pt)
DE (1) DE60105401T2 (pt)
DK (1) DK1267853T3 (pt)
ES (1) ES2228858T3 (pt)
GB (1) GB2348371B (pt)
HU (1) HUP0300130A3 (pt)
MX (1) MXPA02009043A (pt)
PL (1) PL359327A1 (pt)
PT (1) PT1267853E (pt)
RU (1) RU2266111C2 (pt)
SI (1) SI1267853T1 (pt)
TR (1) TR200402661T4 (pt)
WO (1) WO2001068065A2 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7381772B2 (en) * 2003-12-12 2008-06-03 E. I. Du Pont De Nemours And Company Toughened poly(lactic acid) compositions
AU2005252220B2 (en) 2004-06-04 2011-06-02 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
EP1781094B1 (en) 2004-07-07 2016-04-27 Kampavata AB Transgenic non-human animal for use in research models for studying parkinson's disease
AU2006222556B2 (en) * 2005-03-11 2011-09-29 Armaron Bio Pty Ltd Flavonoid compounds and uses thereof
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
TW200843731A (en) 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
AU2008257437A1 (en) * 2007-02-14 2008-12-04 Mars, Incorporated Neurogenic compounds
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN105902535A (zh) * 2009-04-13 2016-08-31 中国医学科学院药物研究所 黄芩素在制备预防和治疗帕金森病药物中的应用
CA2789236C (en) 2009-11-09 2014-09-09 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102755312A (zh) * 2012-07-16 2012-10-31 中国科学院大连化学物理研究所 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN103211832A (zh) * 2013-04-24 2013-07-24 无锡艾德美特生物科技有限公司 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途
CN104116730A (zh) * 2013-04-26 2014-10-29 中国科学院大连化学物理研究所 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用
KR101583399B1 (ko) * 2013-10-22 2016-01-08 충북대학교 산학협력단 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
KR102681552B1 (ko) * 2016-09-27 2024-07-04 (주)아모레퍼시픽 소장 상피세포에서의 카테킨 흡수 증진제
CN111329853A (zh) * 2020-04-21 2020-06-26 遵义医科大学 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物
CN116908319A (zh) * 2023-05-31 2023-10-20 苏州和合医学检验有限公司 一种检测血液中苄丝肼浓度的方法
CN119192117B (zh) * 2024-10-31 2025-09-26 贵州医科大学 一种从马尾松松塔内分离出的黄酮类化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) * 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
JPS6450877A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Oxygen radical catching and removing agent
JPH035423A (ja) * 1989-06-01 1991-01-11 Ichimaru Pharcos Co Ltd フラボノイド含有過酸化脂質生成抑制剤
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
JPH09241637A (ja) * 1996-03-14 1997-09-16 Chugai Pharmaceut Co Ltd 活性酸素ラジカル除去用組成物およびその方法
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
US6537969B1 (en) * 1997-10-24 2003-03-25 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
JPH11323326A (ja) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk 活性酸素消去剤、皮膚保全剤および変色防止剤
FR2787319B1 (fr) * 1998-12-22 2002-06-14 Oreal Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
ES2716404T3 (es) * 2002-01-28 2019-06-12 Kyowa Hakko Kogyo Kk Antagonistas de receptores A2A para su uso en el tratamiento de trastornos del movimiento

Also Published As

Publication number Publication date
KR100738746B1 (ko) 2007-07-12
DE60105401T2 (de) 2005-10-13
US20040242503A1 (en) 2004-12-02
CN1262269C (zh) 2006-07-05
KR20030095184A (ko) 2003-12-18
JP2003526658A (ja) 2003-09-09
CA2402712C (en) 2005-05-17
CN1429109A (zh) 2003-07-09
CZ297123B6 (cs) 2006-09-13
GB0006063D0 (en) 2000-05-03
WO2001068065A9 (en) 2002-07-18
HUP0300130A2 (en) 2003-05-28
EP1267853B1 (en) 2004-09-08
RU2266111C2 (ru) 2005-12-20
DE60105401D1 (de) 2004-10-14
CA2402712A1 (en) 2001-09-20
GB2348371B (en) 2001-04-04
MXPA02009043A (es) 2004-08-19
ES2228858T3 (es) 2005-04-16
WO2001068065A3 (en) 2002-02-21
HUP0300130A3 (en) 2005-11-28
AU5828301A (en) 2001-09-24
JP3677002B2 (ja) 2005-07-27
AU781280B2 (en) 2005-05-12
GB2348371A (en) 2000-10-04
SI1267853T1 (en) 2005-04-30
PT1267853E (pt) 2004-12-31
EP1267853A2 (en) 2003-01-02
DK1267853T3 (da) 2005-01-10
TR200402661T4 (tr) 2004-11-22
WO2001068065A2 (en) 2001-09-20
ATE275397T1 (de) 2004-09-15
AR035567A1 (es) 2004-06-16
CZ20023348A3 (cs) 2003-02-12
PL359327A1 (en) 2004-08-23

Similar Documents

Publication Publication Date Title
PT1267853E (pt) Composicoes que compreendem bloqueadores da transferencia de l-dopa para o exterior de celulas renais, para o tratamenmto da doenca de parkinson
BR0109875A (pt) Tratamento de doenças respiratórias
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
BR9812753A (pt) Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica
BRPI0414481A (pt) métodos de tratamento ou de prevenção da sìndrome das pernas inquietas em um paciente e de melhoria do sono em um paciente com sìndrome das pernas inquietas, e, composição farmacêutica
NO20060416L (no) Ny anvendelse I
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
DK1301201T3 (da) Behandling af glycogenosis type II
BR9712321A (pt) Aminotiofenocarboxamidas
NO20024011L (no) Karbohydratformulering (prebiotisk hjelpemiddel) for å forbedre immunforsvaret
CY1106541T1 (el) Φαρμακευτικη συνθεση και χρηση r-nsaid για αντιμετωπιση φλεγμονης
BRPI0518266B8 (pt) medicamento oral de liberação modificada de pelo menos um princípio ativo sob a forma multimicrocapsular
BR0100949A (pt) Inibição da degradação oxidativa de formulaçõesfarmacêuticas
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
NO954878L (no) Pyrrolderivater
AR025938A1 (es) Nuevas composiciones farmaceuticas.
BR9807950A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto
BRPI0414500A (pt) formulação farmacêutica composição para tratar uma infecção vaginal, e, métodos para tratar uma infecção vaginal, para estabilizar uma formulação de clindamicina, para tratar ou prevenir uma recorrência de uma infecção vaginal em uma paciente e para tratar condições vaginais
BR9912218A (pt) Compostos obtidos de espécies de sálvia possuindo atividade antivirótica
WO2005063195A3 (en) Compositions comprising vitamins and/or derivatives thereof stabilised with olea europea extract and/or ionene polymers
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
PA8531701A1 (es) Derivados de pirimidina
DK1196174T3 (da) Diætmæssigt calcium, som et tilskud til D-vitamin-forbindelsesbehandling af multipel sclerose
ATE364390T1 (de) Verringerung der homocysteinkonzentration im serum mittels allium und vitaminen
NO20051023L (no) Oral administrering av calcitonin

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.